Hyaluronidase, Streptomyces hyalurolyticus
Based on 19 publication(s) in Google Scholar
Hyaluronidase, Streptomyces hyalurolyticus (EC 3.2.1.35) degrades hyaluronan and has been found to be inappropriately regulated during cancer progression. Hyaluronidase randomly cleaves β-N-acetylhexosamine-[1→4] glycosidic bonds in hyaluronic acid, chondroitin, and chondroitin sulfates.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Hyaluronidase, Streptomyces hyalurolyticus
More- Mol Cancer. 2024 Jan 10;23(1):12. [Abstract]
- Adv Mater. 2025 Nov 28:e18378. [Abstract]
- Cancer Res. 2025 Aug 1;85(15):2805-2819. [Abstract]
- Nat Commun. 2023 May 26;14(1):3050. [Abstract]
- Theranostics. 2023 Mar 27;13(6):2040-2056. [Abstract]
- Adv Sci (Weinh). 2025 May;12(20):e2412356. [Abstract]
- J Control Release. 2026 Jun 10:394:114858. [Abstract]
- Cell Death Dis. 2025 Mar 20;16(1):190. [Abstract]
- Mater Today Bio. 2026 Mar 31:38:103086. [Abstract]
- Cell Biosci. 2023 Aug 10;13(1):147. [Abstract]
- J Mol Cell Biol. 2026 Jun 25:mjag019. [Abstract]
- Int J Mol Sci. 2025 Nov 27;26(23):11475. [Abstract]
- Cell Oncol (Dordr). 2024 Dec;47(6):2439-2460. [Abstract]
- Reproduction. 2026 Jan 15;171(1):xaaf013. [Abstract]
- Animals (Basel). 2025 Nov 16;15(22):3304. [Abstract]
- Oral Dis. 2026 Apr 15. [Abstract]
- Drug Dev Ind Pharm. 2023 Feb;49(2):189-206. [Abstract]
- Vet Med Int. 2026 May 21:2026:6119294. [Abstract]
- Preprints. 2025 Nov 26.
-
IHC
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
Biological Activity
Chemical Information
-
SMILES
[Hyaluronidase, Streptomyces hyalurolyticus]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (19)
-
Journal Impact Factor
-
Most Recent
-
Mol Cancer
Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. [Abstract]2024 Jan 10;23(1):12. PMID: 38200517 -
Adv Mater
Disrupting Complement-Inflammation Positive Feedback Circuit via Oligonucleotide Hydrogel Microspheres for Reversing Joint Inflammation. [Abstract]2025 Nov 28:e18378. PMID: 41312643 -
Cancer Res
Pancreatic Neuroendocrine Tumors Secrete Apolipoprotein E to Induce Tip Endothelial Cells That Remodel the Tumor-Stroma Ratio and Promote Cancer Progression. [Abstract]2025 Aug 1;85(15):2805-2819. PMID: 40623046
Hyaluronidase, Streptomyces hyalurolyticus purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Aug 1;85(15):2805-2819. [Abstract]
B, Growth curves of PDX mice treated with PBS, everolimus, PEGPH20 (Hyaluronidase), and everolimus combined with PEGPH20 (n = 5 per group). C, H&E staining and IHC were used to demonstrate the effects of different drug administration strategies on tumor stroma and CD31+ cell and αSMA+ cell number
Hyaluronidase, Streptomyces hyalurolyticus purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Aug 1;85(15):2805-2819. [Abstract]
E and F, Flow cytometry analysis was used to demonstrate the effects of different drug administration strategies on the proportion of TipECs. Hyaluronidase (PEGPH20)
Hyaluronidase, Streptomyces hyalurolyticus purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Aug 1;85(15):2805-2819. [Abstract]
The effects of different drug administration strategies in the BON1+ HUVEC (4:1) model. Hyaluronidase (PEGPH20)
-
Nat Commun
TRABID inhibition activates cGAS/STING-mediated anti-tumor immunity through mitosis and autophagy dysregulation. [Abstract]2023 May 26;14(1):3050. PMID: 37237031 -
Theranostics
Platelets promote CRC by activating the C5a/C5aR1 axis via PSGL-1/JNK/STAT1 signaling in tumor-associated macrophages. [Abstract]2023 Mar 27;13(6):2040-2056. PMID: 37064877 -
Adv Sci (Weinh)
Screening and Identification of Novel DNA Aptamer for Targeted Delivery to Injured Podocytes in Glomerular Diseases. [Abstract]2025 May;12(20):e2412356. PMID: 40178289 -
J Control Release
Hydrogel-immobilized coacervate droplets enable microenvironment-responsive sustained drug release to accelerate diabetic foot ulcers healing. [Abstract]2026 Jun 10:394:114858. PMID: 41881075 -
Cell Death Dis
The role of vitamin K and its antagonist in the process of ferroptosis-damaged RPE-mediated CNV. [Abstract]2025 Mar 20;16(1):190. PMID: 40108164 -
Mater Today Bio
Mannosylated graphene oxide nanotherapeutics co-delivering docetaxel and a STING agonist reprogram myeloid cells and potentiate antitumor immunity. [Abstract]2026 Mar 31:38:103086. PMID: 42006712 -
Cell Biosci
Tumor-derived interleukin-1 receptor antagonist exhibits immunosuppressive functions and promotes pancreatic cancer. [Abstract]2023 Aug 10;13(1):147. PMID: 37563620 -
J Mol Cell Biol
Microtubule-associated CCDC112 is essential for spermiogenesis and male fertility in mice. [Abstract]2026 Jun 25:mjag019. PMID: 42348320 -
Int J Mol Sci
Melatonin Rescues Heat Stress-Induced Suppression of TCA Cycle and Mitochondrial Damage in Goat Sertoli Cells. [Abstract]2025 Nov 27;26(23):11475. PMID: 41373630 -
Cell Oncol (Dordr)
GALNT6 drives lenvatinib resistance in hepatocellular carcinoma through autophagy and cancer-associated fibroblast activation. [Abstract]2024 Dec;47(6):2439-2460. PMID: 39718738 -
Reproduction
2026 Jan 15;171(1):xaaf013. PMID: 41575147 -
Animals (Basel)
Optimization of Hydrogen Peroxide Concentrations for Inducing Oxidative Stress in Bovine Oocytes Prior to In Vitro Maturation. [Abstract]2025 Nov 16;15(22):3304. PMID: 41302012 -
Oral Dis
2026 Apr 15. PMID: 41986910 -
Drug Dev Ind Pharm
Multiple stimulus-response berberine plus baicalin micelles with particle size-charge-release triple variable properties for breast cancer therapy. [Abstract]2023 Feb;49(2):189-206. PMID: 36971392 -
Vet Med Int
Sericin Supplementation Prior to and During In Vitro Maturation Mitigates H2O2-Induced Oxidative Stress in Bovine Oocytes. [Abstract]2026 May 21:2026:6119294. PMID: 42180161 -
Purity & Documentation
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)